Table 6.
Cumulative Incidence at 10 Years of Follow-up for Hepatocellular Carcinoma and Extrahepatic Cancer for Patients With Autoimmune Hepatitis and Matched General-Population Reference Individuals, Sweden 1969–2016
| Group | 10-Year Cumulative Incidence for HCC | 10-Year Cumulative Incidence for Extrahepatic Cancer | ||||||
|---|---|---|---|---|---|---|---|---|
| AIH, % | 95% CI | Comparators, % | 95% CI | AIH, % | 95% CI | Comparators, % | 95% CI | |
| Overall | 2.4 | 1.9, 2.9 | 0.1 | 0.0, 0.1 | 11.2 | 10.3, 12.3 | 8.9 | 8.5, 9.3 |
| Age at diagnosis, years | ||||||||
| 18.0–29.9 | 0.8 | 0.3, 2.2 | 0.0 | 0.0, 0.0 | 4.8 | 3.2, 7.2 | 2.5 | 1.9, 3.2 |
| 30.0–39.9 | 1.1 | 0.5, 2.3 | 0.0 | 0.0, 0.0 | 2.9 | 1.8, 4.6 | 2.3 | 1.8, 3.0 |
| 40.0–49.9 | 1.4 | 0.8, 2.6 | 0.0 | 0.0, 0.0 | 6.6 | 5.0, 8.6 | 4.4 | 3.7, 5.1 |
| 50.0–59.9 | 1.9 | 1.1, 3.1 | 0.1 | 0.0, 0.2 | 11.4 | 9.4, 13.7 | 8.6 | 7.7, 9.5 |
| 60.0–69.9 | 3.8 | 2.7, 5.5 | 0.1 | 0.0, 0.3 | 20.1 | 17.3, 23.3 | 15.7 | 14.6, 16.9 |
| ≥70.0 | 5.1 | 3.5, 7.5 | 0.2 | 0.1, 0.6 | 22.9 | 18.9, 27.7 | 19.9 | 18.2, 21.7 |
| Pathology findings | ||||||||
| Cirrhosis | 7.5 | 5.5, 10.2 | 0.1 | 0.0, 0.4 | 14.4 | 11.5, 18.0 | 10.7 | 9.6, 12.0 |
| Fibrosis | 1.8 | 1.0, 3.3 | 0.0 | 0.0, 0.3 | 14.2 | 11.7, 17.3 | 8.6 | 7.7, 9.7 |
| Inflammation, no fibrosis | 1.6 | 1.1, 2.4 | 0.0 | 0.0, 0.1 | 10.0 | 8.5, 11.7 | 8.8 | 8.1, 9.5 |
| Other | 1.6 | 1.1, 2.5 | 0.1 | 0.0, 0.2 | 10.0 | 8.5, 11.7 | 8.2 | 7.6, 8.9 |
| Necrosis | 1.9 | 0.5, 7.4 | 0.0 | 0.0, 0.0 | 12.3 | 6.9, 21.3 | 7.5 | 5.4, 10.5 |
| Severity of liver disease | ||||||||
| Portal hypertension | 8.4 | 5.0, 14.1 | 0.3 | 0.1, 1.1 | 16.1 | 10.8, 23.7 | 12.9 | 10.9, 15.3 |
| Acute/subacute liver failure | 5.3 | 2.4, 11.6 | 0.0 | 0.0, 0.0 | 13.4 | 8.1, 21.8 | 7.8 | 5.8, 10.5 |
| Overlap syndromes | ||||||||
| PSC | 5.5 | 1.7, 16.7 | 0.0 | 0.0, 0.0 | 11.1 | 4.2, 27.5 | 5.8 | 3.4, 9.8 |
| PBC | 6.2 | 2.7, 13.9 | 0.0 | 0.0, 0.0 | 15.1 | 9.7, 23.2 | 13.9 | 11.1, 17.3 |
Abbreviations: AIH, autoimmune hepatitis; CI, confidence interval; HCC, hepatocellular carcinoma; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.